Cellectis (CLLS) Other financing activities (2022 - 2023)
Cellectis (CLLS) recorded quarterly Other financing activities of $1.3 million in Q2 2023, up 151.98% quarter-over-quarter from $506000.0 in Q1 2023, and up 417.16% on a YoY basis from $246536.8 in Q2 2022.
Cellectis (CLLS) Other financing activities (2022 - 2023) Analysis & Trends
Cellectis' Other financing activities history runs 2 years deep, the most recent figure standing at $1.3 million for Q2 2023.
- In Q2 2023, Other financing activities rose 417.16% year-over-year to $1.3 million; the TTM figure through Dec 2023 stood at $1.8 million (down 79.41% YoY), while the FY2023 annual figure was $1.8 million, down 79.41% from the prior year.
- Other financing activities was $1.3 million for Q2 2023 at Cellectis, up from $506000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $10.6 million in Q1 2022 to a low of -$1.3 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 506,000.00 |
| Mar 31, 2023 | 506,000.00 |
| Dec 31, 2022 | -254,000.00 |
| Dec 31, 2022 | -254,000.00 |
| Sep 30, 2022 | -1.30 Mn |
| Sep 30, 2022 | -1.30 Mn |
| Jun 30, 2022 | -402,000.00 |
| Jun 30, 2022 | -402,000.00 |
| Mar 31, 2022 | 10.61 Mn |
| Mar 31, 2022 | 10.61 Mn |